Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
TE
Tectonic Therapeutic, Inc. Common Stock
TECX
Mkt Cap
$404.7M
Volume
150.73K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
TE
TECX
TE
Tectonic Therapeutic, Inc. Common Stock
TECX
News
·
Tectonic (TECX) Q2 R&D Soars 142%
Mkt Cap
$403.7M
Volume
150.73K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
Tectonic (TECX) Q2 R&D Soars 142%
Biotechnology company Tectonic Therapeutic reported a wider Q2 2025 net loss of $20.0 million, driven by increased clinical trial activities for its lead drug TX45 targeting pulmonary hypertension. Despite higher expenses, the company maintains a strong cash position of $287.4 million, with runway projected into Q4 2028.
The Motley Fool · Aug 8, 2025
Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025
Tectonic Therapeutic announced positive results from a Phase 1b clinical trial of its lead asset TX45 in patients with Group 2 Pulmonary Hypertension in Heart Failure with preserved Ejection Fraction (PH-HFpEF). The data confirmed TX45's tolerability and showed improvements in left ventricular function and pulmonary hemodynamics.
GlobeNewswire Inc. · May 17, 2025
Tectonic Therapeutic Announces Positive Phase 1a Results in AHA 2024 Presentation for TX45, a Long-acting, Fc-Relaxin Fusion Protein
Tectonic Therapeutic announced positive results from the Phase 1a clinical trial of its lead asset, TX45, a long-acting, Fc-relaxin fusion protein. The results support further development of TX45 for the treatment of Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF).
GlobeNewswire Inc. · Nov 11, 2024
Tectonic Therapeutic Announces Favorable Phase 1a Safety, Tolerability and PK/PD Results for Lead Program TX45
Tectonic Therapeutic announced favorable Phase 1a results for its lead program TX45, a long-acting relaxin fusion protein, in the treatment of Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF). The results showed TX45 was well-tolerated with no observed immunogenicity and demonstrated a favorable PK/PD relationship, allowing for the identification of doses for the Phase 2 clinical trial.
GlobeNewswire Inc. · Sep 19, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
TE
TECX
Tectonic Therapeutic, Inc. Common Stock
Buy
Sell
Market
Limit
Soon
TECX
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any TECX yet.
Related Tickers
Earnings